DSGN Design Therapeutics
- 4.175
- +0.015+0.36%
Design Therapeutics News
Larimar Stock Rallies 24% on FDA Removal of Partial Clinical Hold
Design Therapeutics Inc (DSGN) Q1 2024 Earnings: A Detailed Financial and Strategic Review
Hold Rating Maintained for Design Therapeutics Amid Strategic Updates and Financial Review
RBC Capital Reaffirms Their Hold Rating on Design Therapeutics (DSGN)
Design Therapeutics Q1 EPS $(0.20) Beats $(0.29) Estimate
Design Therapeutics (NASDAQ:DSGN) reported quarterly losses of $(0.20) per share which beat the analyst consensus estimate of $(0.29) by 31.03 percent. This is a 42.86 percent increase over losses of
Design Therapeutics | 10-Q: Quarterly report
Design Therapeutics Announces First Quarter 2024 Financial Results and Highlights Upcoming Program Milestones
Starting Phase 1 Development for Fuchs Endothelial Corneal Dystrophy (FECD) in 2024; Observational Study Currently Enrolling Patients
PEGY, MTC and IMTE Among Mid-day Movers
12 Health Care Stocks Moving In Tuesday's Intraday Session
GainersNuwellis (NASDAQ:NUWE) shares rose 57.7% to $0.27 during Tuesday's regular session. The company's market cap stands at $4.1 million. As per the news, the Q1 earnings report came out today. Biov
Design Therapeutics Shares Are Trading Higher After Piper Sandler Upgraded the Stock From Neutral to Overweight and Raised Its Price Target From $6 to $12.
Design Therapeutics Shares Are Trading Higher After Piper Sandler Upgraded the Stock From Neutral to Overweight and Raised Its Price Target From $6 to $12.
Design Therapeutics to Participate in the 2024 RBC Capital Markets Global Healthcare Conference
CARLSBAD, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (NASDAQ:DSGN), a biotechnology company developing treatments for serious degenerative genetic diseases, today announced that management will
Design Therapeutics Price Target Raised to $12.00/Share From $6.00 by Piper Sandler
Design Therapeutics Price Target Raised to $12.00/Share From $6.00 by Piper Sandler
Piper Sandler: Upgraded the Design Therapeutics (DSGN.US) rating from neutral to incremental, and adjusted the target price from $6.00 to $12.00.
Piper Sandler: Upgraded the Design Therapeutics (DSGN.US) rating from neutral to incremental, and adjusted the target price from $6.00 to $12.00.
Piper Sandler Upgrades Design Therapeutics to Overweight, Raises Price Target to $12
Piper Sandler analyst Yasmeen Rahimi upgrades Design Therapeutics from Neutral to Overweight and raises the price target from $6 to $12.
Buy Rating Justified by Design Therapeutics' Innovative Pipeline and Solid Financials
Independent Director of Design Therapeutics Picks Up 88% More Stock
Design Therapeutics And 2 Other Stocks Under $5 Insiders Are Buying
The Dow Jones index closed lower by over 150 points on Monday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders int
Design Therapeutics(DSGN.US) Director Buys US$99,738.48 in Common Stocks
$Design Therapeutics(DSGN.US)$ Director Schmid John P. purchased 26,965 shares of Common Stocks on Mar 22, 25, 2024 at an average price of $3.6988 for a total value of $99,738.48.Source: Announcement
Design Therapeutics(DSGN.US) Director Buys US$4,865.77 in Common Stocks
$Design Therapeutics(DSGN.US)$ Director Berger Heather A. purchased 1,300 shares of Common Stocks on Mar 25, 2024 at an average price of $3.7429 for a total value of $4,865.77.Source: Announcement Wha
Companies Like Design Therapeutics (NASDAQ:DSGN) Are In A Position To Invest In Growth
We can readily understand why investors are attracted to unprofitable companies. For example, although software-as-a-service business Salesforce.com lost money for years while it grew recurring reve
Analysis
Price Target
No Data
